Live and recent posts from across the Fediverse tagged #treatmentresistant, aggregated by home.social.
Rhelion Life Sciences’ Wholly Owned Subsidiary Filament Health Expands Supply Agreement with the University of Chieti-Pescara for PEX010 in the TEMPO Clinical Trial of Psilocybin for Treatment-Resistant Depression in Italy
Followin…
#Italy #Europe #Europa #EU #agreement #chietipescara #clinical #depression #Expands #filament #Health #life #owned #pex #psilocybin #rhelion #sciences #subsidiary #supply #tempo #treatmentresistant #trial #university #wholly
https://www.europesays.com/italy/51041/
DATE: September 19, 2026 at 10:00PM
SOURCE: PSYPOST.ORG
** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------
TITLE: Esketamine-induced dissociation is tied to better outcomes in treatment-resistant depression
Patients with treatment-resistant depression who improved after subcutaneous esketamine treatment reported higher levels of dissociation, particularly feelings that the world seemed unreal or distant, than patients who did not respond, according to a study published in the Journal of Psychiatric Research.
Treatment-resistant depression refers to depression that has not improved after at least two adequate trials of standard antidepressants. Esketamine, a form of ketamine, has emerged as a treatment option for some people with this condition. Ketamine was originally developed as an anesthetic, but researchers later found that it could produce rapid changes in depressive symptoms.
The drug can also cause temporary changes in consciousness. Some patients describe feeling separated from their body or thoughts, while others say that their surroundings seem unreal, distant or dreamlike. These experiences are generally referred to as dissociation. Researchers have debated whether dissociation is simply a side effect of ketamine-based treatment or whether it is connected to the drug’s antidepressant action.
The current study examined data from an open-label clinical trial, meaning both researchers and participants knew what treatment was being administered, at Onofre Lopes University Hospital, affiliated with the Federal University of Rio Grande do Norte in Brazil. Led by Kaike Thiê da C. Gonçalves at the University of São Paulo, the researchers followed adults receiving weekly subcutaneous esketamine.
Of the 30 people originally enrolled, 23 completed all eight treatment sessions and were included in the analysis. The group included 15 females and eight males (average age 34.3 years). Participants initially received 0.5 milligrams of esketamine per kilogram of body weight. The dose could be increased to 0.75 or 1 milligram per kilogram when depressive symptoms had not fallen by at least 50%.
The researchers measured depression before each treatment session and one week after the final session. They assessed dissociation 40 minutes after each dose using a clinician-administered questionnaire. The questionnaire measured overall dissociation as well as three experiences: derealization (feeling that the outside world is unreal); depersonalization (feeling detached from oneself); and amnesia (gaps in memory).
Twelve participants met the study’s definition of a treatment responder, meaning their depression scores fell by at least 50%. Responders had higher overall dissociation scores than the 11 nonresponders across the treatment period. They also reported significantly more derealization. Depersonalization and amnesia were higher among responders as well, but the differences were not statistically significant.
Notably, dissociation levels remained relatively stable across the eight sessions, and the researchers found no significant within-person relationship between dissociation and changes in depression scores. In other words, people who experienced more dissociation than others were more likely to respond, but a person’s dissociation level at a particular session did not reliably predict how much their own symptoms would improve.
The researchers concluded that dissociative experiences, particularly derealization, may represent clinically relevant correlates of antidepressant outcomes. They emphasized that these findings are exploratory and may help guide future research into whether different aspects of altered consciousness are relevant to treatment outcomes.
Several limitations are to be noted. For example, the study did not include a placebo group or blinding. In addition, the analysis also did not fully account for other medications, psychiatric conditions or outside psychotherapy. Importantly, because the researchers increased the dose for patients who were not adequately responding, higher dissociation scores might partly reflect greater cumulative drug exposure rather than a true biological marker of clinical improvement.
The study, “Dissociation and Antidepressant Response to Subcutaneous Esketamine: A Clinical Study,” was authored by Kaike Thiê da C. Gonçalves, Vagner Deuel de O. Tavares, Fernanda Palhano-Fontes, Patrícia Cavalcanti-Ribeiro, Victor Rocha Nóbrega de Almeida, David C. Barbosa, Tatiane Uetti Gomes Fernandes, Eduardo Igor Torquato Cardoso, Nicole Bezerra de Medeiros Lima, Aldielyson Jorge Cavalcante de Brito, Raynara Bolcont, Marcelo Falchi-Carvalho, Emerson Arcoverde, Dráulio Araújo and Nicole Leite Galvão-Coelho.
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #EsketamineDissociation #TreatmentResistant Depression #DerealizationRelief #AntidepressantResponse #KetamineTherapy #DepressionTreatment #DissociationCorrelation #ClinicalStudy #PsychiatricResearch #MentalHealthTreatment
https://www.europesays.com/uk/311279/ Bridging psychiatry and rare genetic diseases: a scoping review of therapeutic strategies and diagnostic delay paired with healthcare economic burden analysis | Orphanet Journal of Rare Diseases #addiction #BehavioralHealth #DiagnosticDelay #general #Genetics #HumanGenetics #Medication #Medicine/PublicHealth #MentalHealth #OrphanDrug #Pharmacology/Toxicology #psychiatric #RareDisease #Science #TreatmentResistant #UK #UnitedKingdom
Ketamine shows promise for severe obsessive-compulsive disorder in new study https://www.psypost.org/ketamine-shows-promise-for-severe-obsessive-compulsive-disorder-in-new-study/?utm_source=dlvr.it&utm_medium=mastodon #Ketamine #OCD #MentalHealth #Psychiatry #TreatmentResistant
Single-dose psilocybin therapy shows promise for veterans with treatment-resistant depression https://www.psypost.org/single-dose-psilocybin-therapy-shows-promise-for-veterans-with-treatment-resistant-depression/?utm_source=dlvr.it&utm_medium=mastodon #SingleDoseTherapy #Psilocybin #Veterans #Depression #TreatmentResistant
https://psychiatryonline.org/doi/10.1176/appi.ajp.2021.21050535 The Neglected Role of Psychotherapy for Treatment-Resistant Depression (Markowitz, et al, 2022) #psychotherapy #depression #neuroscience #psychedelics #ketamine #antidepressants #psychiatry #psychology #treatmentresistant #pharma #fda #mdma #cognitivebehavioraltherapy
NBC News: Aggressive #coloncancer: Newly identified bacteria found in half of tumors may drive growth
A type of bacteria that causes #dentalplaque may be behind a #treatmentResistant form of colorectal cancer, a study published Wednesday in the journal Nature found.
#Ketamine Shows Promise for Hard-to-Treat #Depression in New Study
Research this week presents the most robust evidence to date that ketamine is at least as effective as #electroconvulsivetherapy (#ECT) for patients with #treatmentresistant depression who do not have psychosis.
https://archive.ph/20w3w
#MentalHealth Breakthrough!
👋 hi everyone, happy new year’s! ik that i rly haven’t been present on here so if i take long to respond i’m so sorry 😞 i’ve just haven’t had enough spoons. i’ve been doing better w/my depression but the fatigue & pain lvls are thru the roof 💀 it always seems like when one is doing better the other crashes down…which ofc eventually brings the other down. it’s almost like they can only coexist when they’re both low & i’m running on empty.
i’m trying my best rn & could rly use support in regards to my survival fund 🥺 i’ve had some spoons smtimes but it happens so sporadically and the pain lvl nvr seems to go down. i mean ffs the bruxism is so bad rn that it rips thru an otc mouthguard within’ a week (even the ones that r supposed to be v durable i.e. the athletic ones) & even tho they’re wayyyyyy cheaper than the prescription ones, that shit adds up. but no decent dentist ever accepts medicaid so it’s been y e a r s since my last visit & shits not good 😭 i’ve also realized yesterday that the pain on my tongue whenever i get stressed (lmao aka like 98% of the time), i bite my tongue (& smtimes the insides of my cheeks) in my sleep which w/my damaged teeth like mine its like having mini daggers & so i end u w/mini—but rly painful (+annoying)—slices on my tongue 🙃
anywho—if u have the means to donate gfm &/or cashapp ($jazzafraz) &/or help boost my gfm, it’d rly help. there’s no small amount bc it all adds up in end & every boost counts! so if u could take a sec to help, i’d be extremely grateful ♡
#DisabilityMastodon #Disability #NEISvoid #DisabilityCrowdfund #MutualAidRequest #VoidGives #disabled ##disabledsupport #disabilitymstdn #mutualaid #MutualAidMonday #crowdfunding #chronicillness #ChronicPain #fibromyalgia #survivor #ptsd #chronicfatigue #bpd #DPDR #depression #recovery #eatingdisorder #ADHD #queer #queerean #treatmentresistant #chronicallyill #bdd #donate #borderline #neurodivergent #traumarecovery #traumahealing #traumasurvivor